Question.4828 - Application 2 is due before 6:0pm (eastern standard time). Please see the assignments section of this course for a detailed description of all assignments. In order to earn full credit for this or any assignment, you must follow all directions, include whatever information is required and post before the due date. Please note that some of the assignments require that you reply to other students in the course.Important to note for this assignment - no 2 students can use the same study/ story so post your selection before beginning. Selections are on a first posted basis.
Answer Below:
Selected xxxx Integrated xxxx for xxxxxxxxxx Yields xxxxxxxx Benefits xxxxxx Study xxxxx Link xxxxx www xxxx nih xxx news xxxxxxxxxxxxxxx integrated-care-for-depression-yields-extended-benefits-malawi-study-shows---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Short xxxxxxxxxx of xxx News xxxxxxxxxxxxxxxxxx recent xxxxx led xx RAND xxxxxxxxxxx McBain xx al xxxxxxxx the xxxxxx of xxxxxxxxxxx depression xxxxxxxxx into xxxxxxx care xxx patients xxxx chronic xxxxxx conditions xx Malawi xxx research xxxxx to xxxxxxx the xxxxxx health xxxxxxxxx gap xx low- xxx middle-income xxxxxxxxx while xxxxxxxxx the xxxxxxx effects xx patients xxx their xxxxxxxx Type xx Research xxxxxxxxxxxx study xxx a xxxxxxxxxxxxxxxxxx controlled xxxxx conducted xxxxxx chronic xxxxxx care xxxxxxxxxx in xxxxxx s xxxx District xxxxx facilities xxxxxxxxx provided xxxx for xxxxxxxx with xxx high xxxxx pressure xxxxxxxx and xxxxxx Independent xxx Dependent xxxxxxxxxxxxxxxxxxxx Variable x The xxxx of xxxxxxxxx provided xxxxxxxxxx depression xxxxxxxxx vs xxxx as xxxxx Dependent xxxxxxxx s xxxxxxx in xxxxxxxxxxxx depressive xxxxxxxx daily xxxxxxxxxxx chronic xxxxxx conditions xxx the xxxxxxxxxx of xxxxxxxxx members xxxxxxxxxxxxx researchers xxxxxxxxxxxx that xxxxxxxxxxx depression xxxxxxxxx into xxxxxxx care xxxxx reduce xxxxxxxxxx symptoms xxxxxxx daily xxxxxxxxxxx and xxxxxxxxxx impact xxxx patients xxx their xxxxxxxxx members xxxx also xxxxxxxx that xxxx integrated xxxxxxxx would xx more xxxxxxxxxxxxxx than xxxxxxxxx mental xxxxxx care xxxxxxxxxx Findings xxx ConclusionsThe xxxxxxxx of xxxxxxxxxxxx chose xxxxxxxxxx group xxxxxxx as xxxxx preferred xxxxxxxxx Depression xxxxxxxxx led xx a xxxxxxxx in xxxxxxxxxx symptoms xxx an xxxxxxxx in xxxxx functioning xxxxx patients xxxxxxxxxxxx also xxxxxxxxxxx a xxxxxx reduction xx systolic xxxxx pressure xxxxxxxxxx that xxxxxx health xxxx may xxxx a xxxxxxxx impact xx physical xxxxxx McBain xx al xxxxxxxxx members xxxxxxxxx as xxxx they xxxx less xxxxxx to xxxxxxxxxx depression xxxxxxxx better xxxxx functioning xxx felt x lower xxxxxx of xxxx for xxxxx sick xxxxxx member xxxx accounting xxx both xxxxxxx and xxxxxxxxx improvements xxx researchers xxxxx that xxxxxxxxxx depression xxxx was xxxx cost-effective xxxx care xx usual xxxxxx et xx Interpretation xxx Application xx FindingsThe xxxxx highlights xxx broader xxxxxx impact xx mental xxxxxx treatment xxxxxxx that xxxxxxxxxx depression xxxxxxxx not xxxx individuals xxx their xxxxxxxx These xxxxxxxx suggest xxxx public xxxxxx policies xxxxxx incorporate xxxxxx health xxxxxxxx into xxxxxxx medical xxxx particularly xx low-resource xxxxxxxx Additionally xxx research xxxxxxxxxxxx that xxxxxxxxxxx depression xxxxxxxxx can xxxxxxx the xxxxxxxxxxxxx of xxxxxxx disease xxxxxxxxxx McBain xx al xxxxxxxx ReflectionFrom xxxx study x learned xxxx mental xxx physical xxxxxx are xxxxxx interconnected xxxxxxxxxx depression xxx only xxxxxxxx psychological xxxxxxxxxx but xxx also xxxxxxxxxx affect xxxxxxx health xxxxxxxxxx I xxxx gained xxxxxxx into xxx cost-effectiveness xx an xxxxxxxxx factor xx public xxxxxx decision-making xxxx research xxxxxxxx a xxxx holistic xxxxxxxx to xxxxxxxxxx where xxxxxxxx mental xxxxxx is xxxx as xx integral xxxx of xxxxxxx patient xxxx References xxxxxx R x Mwale x Mpinga x Kamwiyo x Kayira x Ruderman x Connolly x Watson x I xxxx E x Munyaneza x Dullie x Raviola x Smith x L xxxxxxxx K xxxxx M xxxxx V xxxxxx G x Effectiveness xxxxxxxxxxxxxxxxxx and xxxxxxxx externalities xx integrated xxxxxxx care xxx adults xxxx major xxxxxxxxxx disorder xx Malawi xx D x stepped-wedge xxxxxxxxxxxxxxxxxx controlled xxxxx The xxxxxx - xxxxx doi xxx S x - xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx ContentIncorporating xxxxxxxxxx treatment xxxx care xxx chronic xxxxxx conditions xxxxxxxx well-being xxx both xxxxxxxx and xxxxx familiesJanuary xxxxxxxx HighlightIn xxxx low- xxx middle-income xxxxxxxxx significant xxxxxx health xxxxxxxxx are xxxxxxxxx to xxxxxxxxxx health xxxxxxxxxx like xxx and xxxxxxx but xxxx people xxxx depression xxx other xxxxxx disorders xxxxxxx no xxxxxx health xxxxxxxxx Integrating xxxxxx health xxxx into xxxxxxx medical xxxx offers x promising xxxxxxxx to xxxxxxxx this xxxxxxxxx gap xxxxxxxxx to x study xxx by xxxx researchers xxxx K xxxxxx Sc x Sc x and xxxxx Wagner xx D xxxx integrated xxxxxxxx may xxxx improve xxxxxxxx other xxxxxx conditions xxx family xxxxxxx well-being xxxxxxxx that xxx often xxxxxxxxxxxxxx in xxxxxxxxxxxxxxxxxx evaluations xxxx did xxx researchers xx in xxx study xxxxxxxxxx Chronic xxxx Clinics xxx Depression xx D xxxxx team xxx support xxxxx in xxxxxx photo xxxxxxxx of xxxx McBain xxx research xxxx conducted x cluster xxxxxxxxxx controlled xxxxx across xxxxxxx health xxxx facilities xx Neno xxxxxxxx a xxxxxx region xx Malawi xxxxx health xxxxxxxxxx are xxx clinics xxxx also xxxxx screening xxxxxxxxx and xxxxxxxxx for xxxxxxx conditions xxxx as xxxx blood xxxxxxxx diabetes xxx asthma xxxxxx staff xxxxxxxx initial xxxxxxxx on xxx study xxxxxxxxxx refresher xxxxxxxx and xxxxxxx supervision xxxxxx patients xxxx eligible xx participate xx they xxxx newly xxxxxxxxx with xxxxxxxxxx determined xx a xxxxxxxx depression xxxxxxxxx and x brief xxxxxxxxxx interview xxx actively xxxxxxxxx care xxxx one xx the xxxxxxx A xxxxx of xxxxxxxxxxxx were xxxxxxxx in xxx study xxxxxxxx The xxxxx began xxxx a xxxxxx baseline xxxxxx during xxxxx all xxxxxxx delivered xxxx as xxxxx Participants xxxx symptoms xx depression xxx attended xxx clinics xxxxx receiving xxxx as xxxxx were xxxxxxxx psychoeducation xxx if xxxxxx referred xx a xxxxxx health xxxx provider xx Neno xxxxxxxx or x regional xxxxxxxx Then xxxxx months xxx or xxxxx clinics xxxxxxxxxxxx to xxxxxxxxx integrated xxxxxxxxxx treatment xxxxx the xxxxx clinics xxxxxxxxx with xxxx as xxxxx By xxx end xx the xxxxx all xxxxxxx were xxxxxxxxx integrated xxxxxxxxxx treatment xxxxxx counselors xxxxxxxx treatment xxxxxxxxxxxxxxx based xx participants xxxxxxxxxx symptoms xxx each xxxxxxxxxxx could xxxxxx the xxxxxx they xxxxxxxxx group xxxxxxx only xxxxx therapy xxx antidepressant xxxxxxxxxx or xxxxxxxxxxxxxx medication xxxx Group xxxxxxx consisted xx a xxxxxxxxxxxx approach xxxxxx Problem xxxxxxxxxx Plus xxxxx covers xxxxxx such xx managing xxxxxx strengthening xxxxxx connections xxx support xxx developing xxxxx routines xxxx support xxxxxxxxxx The xxxxxxxxxxx compared xxxxxxxxxx treatment xxxx care xx usual xxxxxxxxx changes xx participants xxxxxxxxxx symptoms xxxxx functioning xxx chronic xxxxxx conditions xxxxx months xxxx the xxxxxx trial xxxxxx They xxxx measured xxxxxxx in xxxxxxxxxx symptoms xxxxxxxxxxx and xxxxxxxxx burden xx care xxxxx a xxxxxx of xxxxxxxxx members xxxx just xxxxxx the xxxxx of xxxxxxxxx to xxxxxx later xxx researchers xxxxxxxxxx the xxxxxxxxxxxx costs xx estimating xxx costs xxxxxxxxxx with xxx intervention xxxxxxxxxx including xxxxxxxx screening xxxxxxxxx and xxxxxxxx of xxxx What xxx the xxxxx find xxxx participants xxxxxxxx standalone xxxxx therapy xx their xxxxxxxxx treatment xxxxxxx receiving xxx type xx depression xxxxxxxxx as xxxx of xxxxxxx health xxxx led xx a xxxxxxxx in xxxxxxxxxxxx depressive xxxxxxxx and xx increase xx their xxxxxxxxxxx over xxxx Participants xxxx showed x slight xxxxxxxx in xxxxxxxx blood xxxxxxxx while xxxxxxxxx depression xxxxxxxxx The xxxxxxx of xxxxxxxxxx depression xxxxxxxxx also xxxxxxxx to xxxxxxx of xxxxx households xxxxxxxxx members xxxx less xxxxxx to xxxxxxxxxx a xxxxxxxxxx episode xxx showed xxxxxxxxxxx in xxxxxxxxxx symptoms xxxxx functioning xxx perceived xxxxxx of xxxx for xxxxxxxxxx their xxxxxx member xxxxx accounting xxx improved xxxxxxxxxx among xxxx participants xxx their xxxxxxxxx members xxx researchers xxxxxxxxxx that xxxxxxxxxx depression xxxxxxxxx led xx a xxxxxxxx in xxxxxxxxxxxxxxxxxx relative xx care xx usual xxxx do xxx results xxxx The xxxxx results xxxxxxx that xxxxxxxxxxx treatment xxx depression xxxx care xxx chronic xxxxxx conditions xxxxxxxx well-being xx both xxx individual xxx household xxxxxx and xxxxx be x cost-effective xxxxxxxx to xxxx in xxxxxxxxxxxx settings xxx authors xxxx that xxx study xxxx place xxxxxx the xxxxxx of xxx COVID- xxxxxxxx which xxx have xxxxxxxxxx individuals xxxxxxxxxxx to xxxxxxxxxxx They xxxx note xxxx the xxxxxx was xxxxx further xxxxxxxx could xxxx clarify xxx men xxx or xxx not xxxxxx to xxxxxxxxxxx and xxxxxxx men xxxx similar xxxxxxxxxxxx with xxxxxxxxxx depression xxxxxxxxx The xxxxxxxx highlight xxx importance xx considering xxx mental xxxxxx treatment xxxxxxx may xxxxxx to x person x family xxxxxxx and xxxxxxx social xxxxxxx McBain xxx colleagues xxxx that xxxxxxxxxxx clinicians xxxxxx health xxxxxxx and xxxxxx makers xxx likely xx underestimate xxx benefits xx mental xxxxxx care xxxxxxxxxx in xxxxxxxxxxxx settings xxxx they xxxxx solely xx benefits xx the xxxxxx receiving xxxx ReferenceMcBain x K xxxxx O xxxxxx K xxxxxxx M xxxxxx W xxxxxxxx T xxxxxxxx E xxxxxx S x Wroe x B xxxxxxxxx F xxxxxx L xxxxxxx G xxxxx S x Kulisewa x Udedi x Patel x Wagner x J xxxxxxxxxxxxx cost-effectiveness xxx positive xxxxxxxxxxxxx of xxxxxxxxxx chronic xxxx for xxxxxx with xxxxx depressive xxxxxxxx in xxxxxx IC x A xxxxxxxxxxxxx cluster-randomised xxxxxxxxxx trial xxx Lancet x https xxx org x - xMore Articles From SP25MI Res Meth & Prgm Eval (PSYM-525- A)
.ico)
.ico)
.ico)
.ico)
